Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Array Biopharma

- PMLiVE

Merck buys ArQule for $2.7bn in another cancer bolt-on deal

Deal due to close in the first quarter of 2020

- PMLiVE

Pfizer, Flynn face reinstatement of £90m CMA fine

Facing penalty for dramatic price hikes of an epilepsy drug

- PMLiVE

Pfizer’s Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund

Around 3,200 women in England could be eligible for treatment

- PMLiVE

Novartis acquires The Medicines Company for $9.7bn following takeover rumours

MedCo's cholesterol lowering inclisiran main attraction in planned acquisition

- PMLiVE

The Medicines Company surges on rumours of Novartis takeover

Buyers interested in company as it prepares to file CV drug inclisiran

- PMLiVE

Alkermes boosts CNS presence with $950m Rodin acquisition

Follows company making job cuts in September as part of cost-saving efforts

Celgene building

UPDATED: BMS completes Celgene merger after FTC okay

Approval comes over ten months after acquisition announcement

- PMLiVE

AbbVie sells $30bn of bonds ahead of Allergan merger

Will use net proceeds to fund cash consideration due to shareholders

Understanding the evolving CAR-T market

In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Blue Latitude Health

China flag thumb

Amgen buys BeiGene stake for $2.7bn to aid push into China

China's oncology market forecast to nearly double in size by 2026

- PMLiVE

Pfizer raises forecast following growth of biopharma business

On the flip-side company reported decline in Upjohn generics division

AstraZeneca AZ

AZ reports growth again in Q3, driven by oncology and China sales

Company has also returned to growth in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links